FDA

• VZV post-exposure prophylaxis in high-risk individuals:
  • Immunocompromised children and adults
  • Newborns of mothers with varicella around the time of delivery
  • Premature infants
  • Infants < 1 year of age
  • Adults without evidence of the immunity
  • Pregnant women

• ACIP and AAP recommend administration of VariZIG as soon as possible after exposure and within 10 days[1]
  • The ACIP and AAP recommendations for post-exposure prophylaxis:
    • Immunocompromised patients without evidence of immunity.
    • Newborn infants whose mothers have signs and symptoms of varicella around the time of delivery (i.e., 5 days before to 2 days after delivery).
    • Hospitalized premature infants born at ≥ 28 weeks of gestation whose mothers do not have evidence of immunity to varicella.
    • Hospitalized premature infants born at < 28 weeks of gestation or who weigh ≤1000 g at birth, regardless of their mother’s evidence of immunity to varicella.
    • Pregnant women without evidence of immunity.